Atorvastatin effect on COVID-19 outcomes: a propensity score matched study on hospitalized patients (2025)
- Authors:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.2174/0109298673264305231025093939
- Subjects: ESTUDOS RETROSPECTIVOS; COVID-19; FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO; PACIENTES INTERNADOS
- Agências de fomento:
- Language: Inglês
- Objetivos de Desenvolvimento Sustentável (ODS):
03. Saúde e bem-estar
- Imprenta:
- Source:
- Título: Current Medicinal Chemistry
- ISSN: 0929-8673
- Volume/Número/Paginação/Ano: v. 32, n. 14, p. 2824-2837, 2025
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
POURHOSEINGHOLI, Mohamad Amin et al. Atorvastatin effect on COVID-19 outcomes: a propensity score matched study on hospitalized patients. Current Medicinal Chemistry, v. 32, n. 14, p. 2824-2837, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/87128. Acesso em: 27 jan. 2026. -
APA
Pourhoseingholi, M. A., Yazdani, O., Looha, M. A., Safavi-naini, S. A. A., Esbati, R., Ilkhani, S., et al. (2025). Atorvastatin effect on COVID-19 outcomes: a propensity score matched study on hospitalized patients. Current Medicinal Chemistry, 32( 14), 2824-2837. doi:10.2174/0109298673264305231025093939 -
NLM
Pourhoseingholi MA, Yazdani O, Looha MA, Safavi-naini SAA, Esbati R, Ilkhani S, Taraghikhah N, Hatamabadi H, Sadeghi A, Santos Filho RD dos. Atorvastatin effect on COVID-19 outcomes: a propensity score matched study on hospitalized patients [Internet]. Current Medicinal Chemistry. 2025 ; 32( 14): 2824-2837.[citado 2026 jan. 27 ] Available from: https://observatorio.fm.usp.br/handle/OPI/87128 -
Vancouver
Pourhoseingholi MA, Yazdani O, Looha MA, Safavi-naini SAA, Esbati R, Ilkhani S, Taraghikhah N, Hatamabadi H, Sadeghi A, Santos Filho RD dos. Atorvastatin effect on COVID-19 outcomes: a propensity score matched study on hospitalized patients [Internet]. Current Medicinal Chemistry. 2025 ; 32( 14): 2824-2837.[citado 2026 jan. 27 ] Available from: https://observatorio.fm.usp.br/handle/OPI/87128 - Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps
- Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study
- Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia
- Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study
- Vertebral bone density by quantitative computed tomography mirrors bone structure histomorphometric parameters in hemodialysis patients
- Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia
- Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype [Editorial]: What do genetic defects tell us and what are the clinical implications?
- Sodium intake and prevalence of hypertension in elementary school students
- Clinical Genetic Testing for Familial Hypercholesterolemia
- Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab
Informações sobre o DOI: 10.2174/0109298673264305231025093939 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
